ALX Oncology raises $105 million in Series C financing for CD47 trials

By Akshay Kedari  Date: 2020-02-14

ALX Oncology raises $105 million in Series C financing for CD47 trials

ALX Oncology, a clinical-stage biotechnology company, has secured $105 million in a Series C funding round, led by Vivo Capital. The new investors, who participated in the funding round include Janus Henderson, Logos Capital, Foresite Capital, BVF Partners, HBM Healthcare Investments, and Cormorant Asset Management. The Series C funding round also witnessed the participation of existing investors Lightstone Ventures and Existing investors venBio, who had participated in the previous two rounds.

The latest funds will be used to further phase 2 study of CD47 myeloid checkpoint inhibitor ALX148 along with other anti-cancer treatments. The Series C funding round comes after the revelation of data by ALX on patients suffering from relapsed or refractory non-Hodgkin lymphoma (NHL), who have been treated using ALX148 in combination with rituximab. Among the 21 evaluable subjects, the company observed a median progression-free survival of 7.3 months and an objective response rate of around 43%. The drug was noted to be well tolerated and relatively safe.

Corey Goodman, Co-Founder and Executive Chairman, ALX, reportedly stated that from the initial days, the company believed that it will be the best-in-class in the CD47 checkpoint pathway by utilizing a ‘dead’ Fc domain that does not bind to macrophages, thus lessening the cytopenias and other toxicities related to this class of agents. The company is elated to observe the clinical results supporting its hypothesis and offering the opportunity for higher dosing and increased efficacy, he further added.

The phase 1 study, that generated the lymphoma data is progressing with other arms of the trial testing the potential of CD47 in combination with Keytruda and Herceptin in patients suffering from a solid tumor. But, with ALX148 coming through its first trial in NHL, ALX intends to take the candidate deeper into the clinic. The series C financing proceeds will be used to bankroll the further development of ALX148. 
 

Source links:

https://www.fiercebiotech.com/biotech/alx-raises-105m-for-midphase-trials-cd47-cancer-drug

 

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Tiger Global looking to raise USD 10 billion to create new venture fund

Tiger Global looking to raise USD 10 billion to create new venture fund

By Akshay Kedari

American investment firm Tiger Global is reportedly looking to create a capital fund for startups by securing USD 10 billion from investors. So far, the company has participated in over 100 investment rounds since the past three months and has manage...

Urban Company secures USD 190 million in funding round led by Prosus

Urban Company secures USD 190 million in funding round led by Prosus

By Akshay Kedari

Urban Company, an Indian gig marketplace that provides home maintenance services, has secured USD 190 million in a funding round which was led by Prosus N.V. Other participants in the fundraising included companies such as Steadview Capital, Tiger Gl...

Samsung might launch a foldable Android tablet in first quarter of 2022

Samsung might launch a foldable Android tablet in first quarter of 2022

By Akshay Kedari

After introducing three foldable smartphones in the past couple of years, South Korean multinational conglomerate Samsung Electronics is reportedly working on its first tri-folding Android tablet. According to reliable sources, the new product is lik...

Remote hiring startup Deel secures USD 156 million in Series C funding

Remote hiring startup Deel secures USD 156 million in Series C funding

By Akshay Kedari

Deel, a company that specializes in offering recruitment, payroll, and compliance tools, has reportedly secured USD 156 million during a Series C funding round which was led by YC Continuity Fund. The California-based startup has now reached a valuat...

Audi unveils the A6 e-Tron concept with 700 km range and 800 Nm torque

Audi unveils the A6 e-Tron concept with 700 km range and 800 Nm torque

By Akshay Kedari

Audi AG, a German multinational auto manufacturer of luxury vehicles has unveiled the A6 e-Tron concept which is soon likely to be made available globally. The production version which is expected to have a range of 700 km (more than 400 miles) is to...